UBS Starts Cogent (COGT) at Buy

UBS analyst Michael Yee initiates coverage on Cogent (NASDAQ: COGT) with a Buy rating and a price target of $60.00.

The analyst comments: "We initiate at BUY and see unique scarcity value and strategic value of a smid-cap biotech going to the FDA in 2026 with not one but two different potential blockbuster filings – positive Phase III data in 2L GIST cancer and positive Phase III data in indolent mastocytosis too. We see potential for ~$2B + for COGT bezu in GIST based on strong positive Phase III data in 2L GIST in an underserved market with unmet need and clear differentiation over Sutent standard-of-care. ISM indication is another ~$1B opportunity with FDA approval potential in 2026 + long-term competitiveness vs. BPMC Ayvakit (acquired by SNY)."

For an analyst ratings summary and ratings history on Cogent click here. For more ratings news on Cogent click here.

Shares of Cogent closed at $34.78 yesterday.

You May Also Be Interested In